A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 10, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

October 22, 2018

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Abemaciclib

Administered orally

Trial Locations (36)

1000

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels

3000

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven

4000

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège

6000

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi

10065

Memorial Sloan Kettering Cancer Center, New York

20010

Washington Hospital Center, Washington D.C.

21034

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon

21044

Maryland Oncology Hematology, P.A., Columbia

28007

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid

33176

Advanced Medical Specialties, Miami

33705

Florida Cancer Specialists, St. Petersburg

33916

Florida Cancer Specialists, Fort Myers

37203

Sarah Cannon Research Institute SCRI, Nashville

45242

Oncology Hematology Care Inc, Cincinnati

46015

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia

55404

Minnesota Oncology/Hematology PA, Minneapolis

75093

Texas Oncology-Plano West, Plano

75231

Presbyterian Hospital Dallas, Dallas

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

75248

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris

75702

Tyler Cancer Center, Tyler

76022

Texas Oncology - Bedford, Bedford

76104

The Center for Cancer and Blood Disorders, Fort Worth

77024

Texas Oncology-Memorial City, Houston

77380

US Oncology, The Woodlands

78731

Texas Oncology Cancer Center, Austin

80220

Rocky Mountain Cancer Center, Denver

85704

HOPE Hematology Oncology Physicians and Extenders, Tucson

85715

Arizona Clinical Research Center, Tucson

86336

Northern Arizona Hematology & Oncology Associates, Sedona

93105

Sansum Medical Research Foundation, Santa Barbara

94115

Univ of California San Francisco, San Francisco

98684

Northwest Cancer Specialists PC, Vancouver

02115

Dana Farber Cancer Institute, Boston

75090-0504

Texas Oncology-Sherman, Sherman

08035

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02102490 - A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread | Biotech Hunter | Biotech Hunter